BTMD biote Corp.

NEUTRAL Impact: 4/10 8-K
Horizon weeks Filed Jun 2, 2026 Processed 12d 11h ago SEC 0001193125-26-253858
8-K context-dependent: Items 5.02, 7.01
Latest settled — T+1d
BTMD ▲ +11.85% at T+1d
NEUTRAL call ✓ call won +11.85% · α vs SPY +11.45% · entry $2.11 → $2.36
Next anchor: T+5d due 6d ago
Last close $2.46 (close Jun 12) · +16.59% from $2.11 entry
Entry anchored
Jun 2, 2026
via day open
T+1d
+11.85%
call +11.85% · α +11.45%
$2.36
settled 12d ago
T+5d
call — · α —
due 6d ago
T+20d
call — · α —
in 16d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

CEO Bret Christensen resigned for family/personal reasons effective June 8, 2026, and will remain on the board. CFO/Chief Business Officer Robert Peterson was appointed interim CEO, and Chairman Marc Beer was named Executive Chairman with a $521,200 base salary and option grant for 114,157 shares. The company reaffirmed full-year 2026 guidance for revenue above $190 million and Adjusted EBITDA above $38 million. The CEO departure is orderly with continuity, but the interim nature of the CEO role and the search for a new CFO introduce execution risk.

Actionable Insight

The leadership transition is orderly with internal promotion and guidance reaffirmation, reducing near-term disruption risk. However, the dual role of Peterson as interim CEO and CFO, plus the search for a permanent CFO, creates overhang. Monitor for CFO appointment and Q2 2026 results for procedure revenue growth trajectory.

Key Facts

  • CEO Bret Christensen resigned effective June 8, 2026, for family/personal reasons; no disagreement with company operations.
  • CFO/Chief Business Officer Robert Peterson appointed Interim CEO and director, effective June 8, 2026.
  • Chairman Marc Beer appointed Executive Chairman effective June 8, 2026, with $521,200 annual base compensation and option for 114,157 shares.
  • Company reaffirmed FY2026 guidance: revenue above $190 million, Adjusted EBITDA above $38 million, return to procedure revenue growth in H2 2026.
  • Board retained executive search firm to identify CFO candidates (Peterson is currently CFO and interim CEO).
  • Christensen received option to purchase 130,000 shares as part of separation agreement; remains Class III director until 2028 annual meeting.

Financial Impact

FY2026 guidance reaffirmed: revenue above $190M, Adjusted EBITDA above $38M. No change to financial outlook.

revenueadjusted_ebitda

Risk Factors

  • Interim CEO also serving as CFO creates key-person risk and potential distraction.
  • Permanent CFO search could signal difficulty in attracting talent or reveal undisclosed issues.
  • Guidance reaffirmation is verbal only — no hard financials filed; execution risk remains.

Market Snapshot

Exchange
Nasdaq
Sector
Medicinal Chemicals & Botanical Products
Analyst Consensus
82% bullish (11 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-253858
Document: d215108dex991.htm0001193125-26-253858
Document: 0001193125-26-253858-index-headers.html0001193125-26-253858
Document: 0001193125-26-253858-index.html0001193125-26-253858
Document: 0001193125-26-253858.txt0001193125-26-253858
2 reports for BTMD
Performance horizon
Filters
Rows
Reports for BTMD — sortable, filterable
Type Now
Jun 2, 2026
12d ago
8-K
NEUTRAL ★ 4/10
$2.11 $2.36▲ +11.85%▲ +11.45%$2.46 (+16.59%)
Apr 3, 2026
10w ago
8-K
NEUTRAL ★ 4/10
$1.64 $1.49▼ −9.15%▼ −9.21%$2.46 (+50.00%)
Showing 2 of 2

US Market Status

Market Closed — Opens in 4h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access